Clinical Trial SuccessThe ARCHER study results bring important, additional proof-of-concept data on the anti-inflammatory effect of CardiolRx in a second indication.
Drug Safety And ToleranceCardiolRx was well-tolerated with no new safety signals observed, enhancing its attractiveness.
Market ValuationCRDL's current market cap does not reflect the positive outcomes of the ARCHER trial, suggesting an undervaluation of the stock.